{
    "clinical_study": {
        "@rank": "122598", 
        "arm_group": [
            {
                "arm_group_label": "Normoglycaemia followed by hypoglycaemia", 
                "arm_group_type": "Other"
            }, 
            {
                "arm_group_label": "Hypoglycaemia followed by normoglycaemia", 
                "arm_group_type": "Other"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to investigate the impact of low\n      blood sugar during the night on sleep in subjects with type 2 diabetes."
        }, 
        "brief_title": "A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Hypoglycemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 24 weeks  prior to\n             screening\n\n          -  Currently treated with any anti-diabetic treatment (incl. diet and exercise) except\n             insulin with a stable dose for more than 4 weeks prior to screening\n\n          -  Body mass index below 35 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Severe hypoglycaemic event during the past 6 months or hospitalisation for diabetic\n             ketoacidosis during the previous 6 months\n\n          -  Any other chronic disorder or severe disease by clinical information (including\n             chronic obstructive pulmonary disease (COPD), sleep apnoea and epilepsy) which, in\n             the opinion of the investigator might jeopardise subject's sleep, safety or\n             compliance with the protocol, or subjects with mental incapacity or language barriers\n             precluding adequate understanding or co-operation or who, in the opinion of the\n             investigator, should not participate in the trial\n\n          -  Use of antidepressants, antipsychotics, hypnotics, sedatives or other drugs known to\n             influence sleep within 12 weeks prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780272", 
            "org_study_id": "NN1250-3997", 
            "secondary_id": "U1111-1127-4819"
        }, 
        "intervention": {
            "arm_group_label": [
                "Normoglycaemia followed by hypoglycaemia", 
                "Hypoglycaemia followed by normoglycaemia"
            ], 
            "description": "Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid\u00ae)). Plasma glucose will be monitored.", 
            "intervention_name": "glucose clamp", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 8, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Glostrup", 
                    "country": "Denmark", 
                    "zip": "2600"
                }
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Denmark: Danish Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "The number of electroencephalogram (EEG) identified arousals", 
            "safety_issue": "No", 
            "time_frame": "During the first four hours (0-4 hours) after reaching sleep stage N2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780272"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time spent in the different sleep stages (% of total sleep time): Sleep stage N1, Sleep stage N2, Sleep stage N3 and Rapid Eye Movement (REM) sleep", 
                "safety_issue": "No", 
                "time_frame": "During the first four hours (0-4 hours) after reaching sleep stage N2"
            }, 
            {
                "measure": "Total sleep time", 
                "safety_issue": "No", 
                "time_frame": "0-8 hours"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}